Precision approach in apoA-I infusion trials: When CSL112 may actually work

Area of Science:

• Cardiovascular Medicine
• Biochemistry
• Pharmacology

Background:

• The ApoA-I Event Reducing in Ischemic Syndromes II trial found CSL112 (apoA-I infusion) ineffective for major cardiovascular events in all post-myocardial infarction patients.
• Exploratory analyses indicated potential benefits in specific patient subgroups with high LDL-C and systemic inflammation.

Purpose of the Study:

• To investigate the critical role of elevated LDL-C and systemic inflammation in CSL112 efficacy.
• To propose a precision-stratification framework for future apoA-I infusion trials based on ATP-binding cassette transporter A1 (ABCA1) biology.
• To explore patient selection strategies and combination therapies for impaired ABCA1 function.

Main Methods:

• Integrating ABCA1 transporter biology with subgroup trial data.
• Analyzing the interplay of lipid burden and inflammation on ABCA1 function.
• Evaluating ex vivo efflux assays and molecular transporter profiling for patient selection.

Main Results:

• CSL112 efficacy appears contingent on the co-occurrence of elevated LDL-C and systemic inflammation.
• Statin therapy may downregulate ABCA1 transporter function.
• Future trials may benefit from stratifying patients based on ABCA1 transporter status.

Conclusions:

• Precision medicine approaches are crucial for optimizing apoA-I infusion therapy.
• Targeting ABCA1 transporter function, potentially with combination therapies, could enhance cardiovascular outcomes.
• Further research into patient stratification and combination therapies is warranted.